Spots Global Cancer Trial Database for azd1775
Every month we try and update this database with for azd1775 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy | NCT02448329 | Advanced Gastri... | AZD1775 paclitaxel | - 20 Years | Samsung Medical Center | |
| Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients | NCT02593019 | Small Cell Lung... | AZD1775 | 20 Years - | Samsung Medical Center | |
| A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer | NCT02087176 | Previously Trea... | AZD1775 AZD1775 Placebo Antimitotic Age... pegfiligrastim | 18 Years - | AstraZeneca | |
| AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma | NCT03668340 | Uterine Cancer | AZD1775 | 18 Years - | Dana-Farber Cancer Institute | |
| Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | NCT02610075 | Locally Advance... Metastatic Soli... Ovarian Cancer | AZD1775 | 18 Years - 130 Years | AstraZeneca | |
| Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer | NCT02087241 | Previously Untr... | AZD1775 AZD1775 Matchin... pemetrexed carboplatin | 18 Years - | AstraZeneca | |
| Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy | NCT02448329 | Advanced Gastri... | AZD1775 paclitaxel | - 20 Years | Samsung Medical Center | |
| Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | NCT02610075 | Locally Advance... Metastatic Soli... Ovarian Cancer | AZD1775 | 18 Years - 130 Years | AstraZeneca | |
| Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | NCT02341456 | Advanced Solid ... | AZD1775 Paclitaxel carboplatin | 18 Years - 100 Years | AstraZeneca | |
| OLAParib COmbinations | NCT02576444 | Cancer | AZD2281 AZD5363 AZD1775 AZD6738 | 18 Years - | Yale University | |
| Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC | NCT02585973 | Carcinoma, Squa... | AZD1775 Cisplatin Intensity Modul... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | NCT02194829 | Metastatic Panc... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | AZD1775 Gemcitabine Nab-paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 0 Study of AZD1775 in Recurrent GBM Patients | NCT02207010 | Glioblastoma GBM | AZD1775 | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer | NCT03028766 | Hypopharynx Squ... Oral Cavity Squ... Larynx Cancer | AZD1775 Cisplatin Radiotherapy | 18 Years - 70 Years | University of Birmingham | |
| AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | NCT02511795 | Refractory Soli... Relapsed Small ... | AZD1775 Olaparib | 18 Years - 130 Years | AstraZeneca | |
| CISPLATIN + AZD-1775 In Breast Cancer | NCT03012477 | Triple-negative... | Cisplatin AZD1775 | 18 Years - | Dana-Farber Cancer Institute | |
| AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma | NCT03668340 | Uterine Cancer | AZD1775 | 18 Years - | Dana-Farber Cancer Institute | |
| OLAParib COmbinations | NCT02576444 | Cancer | AZD2281 AZD5363 AZD1775 AZD6738 | 18 Years - | Yale University | |
| Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients | NCT02593019 | Small Cell Lung... | AZD1775 | 20 Years - | Samsung Medical Center | |
| Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | NCT02610075 | Locally Advance... Metastatic Soli... Ovarian Cancer | AZD1775 | 18 Years - 130 Years | AstraZeneca | |
| Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | NCT02617277 | Advanced Solid ... | AZD1775 MEDI4736 | 18 Years - 130 Years | AstraZeneca | |
| AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer | NCT02513563 | Lung Cancer | Carboplatin Paclitaxel AZD1775 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer | NCT02087241 | Previously Untr... | AZD1775 AZD1775 Matchin... pemetrexed carboplatin | 18 Years - | AstraZeneca | |
| Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation | NCT02688907 | Small Cell Lung... | AZD1775 | 20 Years - | Samsung Medical Center | |
| Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | NCT02906059 | Metastatic Colo... | AZD1775 Irinotecan | 18 Years - | NYU Langone Health | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | NCT02511795 | Refractory Soli... Relapsed Small ... | AZD1775 Olaparib | 18 Years - 130 Years | AstraZeneca | |
| AZD1775 for Advanced Solid Tumors | NCT01748825 | Solid Tumors | MK-1775 (AZD177... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | NCT02194829 | Metastatic Panc... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | AZD1775 Gemcitabine Nab-paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
